Developer docs
API playgroundTry for free, no card

Search company profiles

Corwave

Full company profile

uuid0000c47

Namestring
Corwave
Legal namestring
CorWave SA
Websiteurl
corwave.com
Company typeenum
Private
Founded yearint
2012
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersClichy, France
HQ citystring
Clichy
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiac assist devices, left ventricular assist system, implantable heart pumps, mechanical circulatory support, wave membrane technology
Industry2 codes
PRIMARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Cardiac Assist Devices (LVAD)
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Cardiac Assist Devices (pre-commercial)
TypeHardware Sales
Description

CorWave is a clinical-stage company that has not yet generated commercial revenue. Its LVAD device is investigational and not approved for commercial use in any country. The company is preparing for pivotal trials and eventual commercialization of its LVAD and Nemo products.

aijourn.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

CorWave is a clinical-stage medical device company developing implantable cardiac assist pumps based on its proprietary wave membrane technology. The flagship offering is the CorWave LVAS (Left Ventricular Assist System), an implantable LVAD that uses an undulating membrane to produce physiological pulsatile blood flow for patients with advanced heart failure. A second product, Nemo, extends the wave membrane platform to mini-invasive circulatory support applications. All products are currently investigational and not approved for commercial use in any country.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Successfully completed first chronic 60-day preclinical study in 2019, followed by 90-day in vivo study in 2021 with native heart synchronization
+1 more record
Product overview1 text field

CorWave is a clinical-stage medical device company that has developed a portfolio of cardiac assist products centered on its proprietary wave membrane technology. The core technology is the Wave Membrane, which provides pulsatile blood flow by mimicking the undulating motion of marine animals. The primary product is the CorWave LVAS (Left Ventricular Assist System), an implantable LVAD that uses this technology to treat advanced heart failure patients. A second product, Nemo, extends the wave membrane technology to mini-invasive circulatory support applications. All products are currently investigational and not approved for commercial use.

Product and service3 records
1Wave Membrane
CategoryCore Technology Platform
Description

A disruptive membrane technology that produces truly pulsatile blood flow by undulating like fish fins, replacing traditional rotary pumps and reducing friction and shear forces. Forms the technological basis for CorWave's LVAD and Nemo products.

2CorWave LVAS
CategoryImplantable Cardiac Assist Device
Description

Left Ventricular Assist System (LVAD) using wave membrane technology. An implantable heart assist pump connected to the left ventricle, designed to treat patients with advanced heart failure by reproducing physiological pulse and blood flow velocities similar to a healthy heart. Currently an investigational device not approved for commercial use.

3Nemo
CategoryCardiac Assist Device
Description

A mini-invasive cardiac pump using wave membrane technology for circulatory support for heart conditions beyond LVAD applications. Extends CorWave's wave membrane platform to broader cardiac indications.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Clinical R&D partner for the CALYPSO program, working on CorWave LVAD development for severe heart failure patients. Part of a PSPC (Structuring Project for Competitive Solutions) funded by Bpifrance.

2AP-HP Pitié-Salpêtrière Hospital
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Clinical R&D partner for the CALYPSO program alongside Lille University Hospital. Key cardiac surgery center involved in CorWave device development and testing.

corwave.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2012-01-01
Description

Startup studio that founded CorWave in 2012 with exclusive license agreement with AMS R&D for the wave membrane technology. Led by Gérard Hascoët and Tim Lenihan.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Abbott
TypeBroad incumbent
Description

Abbott acquired Thoratec and markets HeartMate 3, the dominant continuous-flow LVAD and CorWave's primary direct competitor. Comparable because it sells into the same cardiac surgery / advanced heart failure call point with an implantable mechanical circulatory support device, but operates a broad diagnostics and device portfolio.

TypeBroad incumbent
Description

Previously commercialized the HVAD LVAD (acquired via HeartWare; HVAD withdrawn in 2021) and remains active in cardiac surgery and heart failure. Comparable as a major cardiac device incumbent that has shipped LVAD-class products to the same surgical centers CorWave targets.

3Carmat
TypeDirect peer
Description

French clinical-stage company developing a total artificial heart for end-stage biventricular heart failure. Comparable as a French, clinical-stage cardiac assist implant developer targeting the same advanced heart failure patient population and surgeon customer base.

TypeDirect peer
Description

US-based developer of the SynCardia total artificial heart, the most widely implanted TAH in the world. Comparable as a developer of a mechanical implantable cardiac assist device serving end-stage heart failure patients treated by cardiac surgeons.

TypeDirect peer
Description

Now part of J&J MedTech, Abiomed markets the Impella family of percutaneous mechanical circulatory support devices used in high-risk PCI and cardiogenic shock. Comparable as a mechanical circulatory support franchise addressing advanced heart failure and cardiac surgery patients, though percutaneous rather than implantable.

6Evaheart
TypeDirect peer
Description

Japanese company developing a next-generation implantable LVAD using a centrifugal, hydrodynamically suspended impeller, currently in clinical use in Japan and pursuing US approval. Comparable as a developer of a novel implantable LVAD competing against HeartMate 3 in the same surgical indication.

7Berlin Heart
TypeDirect peer
Description

German manufacturer of the EXCOR ventricular assist device, primarily used as a pediatric and bridge-to-transplant VAD. Comparable as a European mechanical circulatory support company selling implantable VADs to cardiac surgeons and heart failure specialists.

TypeEmerging player
Description

UK-based early-stage company developing a next-generation miniaturised rotary LVAD. Comparable as a small European LVAD developer pursuing a pulsatile/low-shear design thesis similar to CorWave's, targeting the same advanced heart failure implant market.

TypeOthers
Description

Cardiac surgery and neuromodulation device company with a legacy in cardiopulmonary bypass and heart valves. Comparable as a cardiac surgery device peer relevant to CorWave's hospital procurement and cardiac surgeon customer channel, though not an LVAD competitor.

TypeOthers
Description

US-based contract manufacturer specializing in active implantable medical devices, including components for ventricular assist devices. Comparable as a supplier/manufacturing partner in the LVAD supply chain rather than a direct competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Corwave

Cardiac Assist Devices (LVAD)corwave.com

Corwave firmographics

Firmographics
Name
Corwave
Legal name
CorWave SA
Website
https://corwave.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Corwave industry classification

Industry
Product category
Cardiac Assist Devices (LVAD)
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Cardiac assist devices
  • Left ventricular assist system
  • Implantable heart pumps
  • Mechanical circulatory support
  • Wave membrane technology

Where Corwave is headquartered

Location

Headquarters

HQ city
Clichy
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Corwave business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Others

Revenue model

  1. Cardiac Assist Devices (pre-commercial): CorWave is a clinical-stage company that has not yet generated commercial revenue. Its LVAD device is investigational and not approved for commercial use in any country. The company is preparing for pivotal trials and eventual commercialization of its LVAD and Nemo products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Corwave product offering

Product offering

Core offering

CorWave is a clinical-stage medical device company developing implantable cardiac assist pumps based on its proprietary wave membrane technology. The flagship offering is the CorWave LVAS (Left Ventricular Assist System), an implantable LVAD that uses an undulating membrane to produce physiological pulsatile blood flow for patients with advanced heart failure. A second product, Nemo, extends the wave membrane platform to mini-invasive circulatory support applications. All products are currently investigational and not approved for commercial use in any country.

Product overview

CorWave is a clinical-stage medical device company that has developed a portfolio of cardiac assist products centered on its proprietary wave membrane technology. The core technology is the Wave Membrane, which provides pulsatile blood flow by mimicking the undulating motion of marine animals. The primary product is the CorWave LVAS (Left Ventricular Assist System), an implantable LVAD that uses this technology to treat advanced heart failure patients. A second product, Nemo, extends the wave membrane technology to mini-invasive circulatory support applications. All products are currently investigational and not approved for commercial use.

Differentiator

Problem solved

Functional benefit

Products and services

  • Wave Membrane A disruptive membrane technology that produces truly pulsatile blood flow by undulating like fish fins, replacing traditional rotary pumps and reducing friction and shear forces. Forms the technological basis for CorWave's LVAD and Nemo products.
  • CorWave LVAS Left Ventricular Assist System (LVAD) using wave membrane technology. An implantable heart assist pump connected to the left ventricle, designed to treat patients with advanced heart failure by reproducing physiological pulse and blood flow velocities similar to a healthy heart. Currently an investigational device not approved for commercial use.
  • Nemo A mini-invasive cardiac pump using wave membrane technology for circulatory support for heart conditions beyond LVAD applications. Extends CorWave's wave membrane platform to broader cardiac indications.

Quantifiable outcome

  • Successfully completed first chronic 60-day preclinical study in 2019, followed by 90-day in vivo study in 2021 with native heart synchronization
  • +1 more outcomes

Companies that use Corwave

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Corwave technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Corwave partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Lille University Hospital (CHU de Lille)coreStrategic or Co-development Partner · 1 January 2018Clinical R&D partner for the CALYPSO program, working on CorWave LVAD development for severe heart failure patients. Part of a PSPC (Structuring Project for Competitive Solutions) funded by Bpifrance.
  • AP-HP Pitié-Salpêtrière HospitalcoreStrategic or Co-development Partner · 1 January 2018Clinical R&D partner for the CALYPSO program alongside Lille University Hospital. Key cardiac surgery center involved in CorWave device development and testing.
  • MD StartcoreStrategic or Co-development Partner · 1 January 2012Startup studio that founded CorWave in 2012 with exclusive license agreement with AMS R&D for the wave membrane technology. Led by Gérard Hascoët and Tim Lenihan.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Corwave competitors and assessment

Company assessment

Broad incumbents

  • Abbott: Abbott acquired Thoratec and markets HeartMate 3, the dominant continuous-flow LVAD and CorWave's primary direct competitor. Comparable because it sells into the same cardiac surgery / advanced heart failure call point with an implantable mechanical circulatory support device, but operates a broad diagnostics and device portfolio.
  • Medtronic: Previously commercialized the HVAD LVAD (acquired via HeartWare; HVAD withdrawn in 2021) and remains active in cardiac surgery and heart failure. Comparable as a major cardiac device incumbent that has shipped LVAD-class products to the same surgical centers CorWave targets.

Direct peers

  • Carmat: French clinical-stage company developing a total artificial heart for end-stage biventricular heart failure. Comparable as a French, clinical-stage cardiac assist implant developer targeting the same advanced heart failure patient population and surgeon customer base.
  • SynCardia Systems: US-based developer of the SynCardia total artificial heart, the most widely implanted TAH in the world. Comparable as a developer of a mechanical implantable cardiac assist device serving end-stage heart failure patients treated by cardiac surgeons.
  • Abiomed (Johnson & Johnson MedTech): Now part of J&J MedTech, Abiomed markets the Impella family of percutaneous mechanical circulatory support devices used in high-risk PCI and cardiogenic shock. Comparable as a mechanical circulatory support franchise addressing advanced heart failure and cardiac surgery patients, though percutaneous rather than implantable.
  • Evaheart: Japanese company developing a next-generation implantable LVAD using a centrifugal, hydrodynamically suspended impeller, currently in clinical use in Japan and pursuing US approval. Comparable as a developer of a novel implantable LVAD competing against HeartMate 3 in the same surgical indication.
  • Berlin Heart: German manufacturer of the EXCOR ventricular assist device, primarily used as a pediatric and bridge-to-transplant VAD. Comparable as a European mechanical circulatory support company selling implantable VADs to cardiac surgeons and heart failure specialists.

Emerging players

  • Calon Cardio-Technology: UK-based early-stage company developing a next-generation miniaturised rotary LVAD. Comparable as a small European LVAD developer pursuing a pulsatile/low-shear design thesis similar to CorWave's, targeting the same advanced heart failure implant market.

Others

  • LivaNova: Cardiac surgery and neuromodulation device company with a legacy in cardiopulmonary bypass and heart valves. Comparable as a cardiac surgery device peer relevant to CorWave's hospital procurement and cardiac surgeon customer channel, though not an LVAD competitor.
  • Cirtec Medical: US-based contract manufacturer specializing in active implantable medical devices, including components for ventricular assist devices. Comparable as a supplier/manufacturing partner in the LVAD supply chain rather than a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Corwave social profiles

Digital presence

Corwave compliance and trust

Trust signal

Compliance1 record

Corwave financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Corwave leadership team

Management profile

Number of profiles

Profiles12 records

Corwave funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Corwave M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Corwave

What does Corwave do?

CorWave is a clinical-stage medical device company developing implantable cardiac assist pumps based on its proprietary wave membrane technology. The flagship offering is the CorWave LVAS (Left Ventricular Assist System), an implantable LVAD that uses an undulating membrane to produce physiological pulsatile blood flow for patients with advanced heart failure. A second product, Nemo, extends the wave membrane platform to mini-invasive circulatory support applications. All products are currently investigational and not approved for commercial use in any country.

Is Corwave a public or private company?

Corwave is a private company. It is classified as venture growth investor backed and is currently operating.

When was Corwave founded?

Corwave was founded in 2012. It employs 101 to 250 people.

Where is Corwave based?

Corwave is headquartered in Clichy, France, in the Europe region.

How does Corwave make money?

One revenue line is on record: cardiac Assist Devices (pre-commercial).

Who are Corwave's main competitors?

Broad incumbents on record are Abbott and Medtronic. Direct peers are Carmat, SynCardia Systems, Abiomed (Johnson & Johnson MedTech), Evaheart and Berlin Heart. Calon Cardio-Technology is listed as an emerging player. Others are LivaNova and Cirtec Medical.

Does Corwave have an API?

No public API is recorded for Corwave.

What industry is Corwave in?

Corwave's product category is Cardiac Assist Devices (LVAD). Its primary akta.pro industry code is HLAHAFAG, Mechanical Circulatory Support (VAD, IABP, ECMO), with a secondary code of HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AijournCorWave Achieves Major Regulatory Milestone with ISO 13485 Certification Across its Entire OperationsCorWave, a French clinical-stage medical company, has received ISO 13485 certification from an independent notified body for its Quality Management System covering the design, development, manufacturing, distribution, and servicing of its Left Ventricular Assist Devices. The certification, described as a foundational regulatory milestone on the path to commercialization, validates the company's operational and organizational maturity across its entire product lifecycle. According to CEO Louis de Lillers, this achievement enables CorWave to approach its pivotal trial with confidence and will be decisive for commercial deployment of its cardiac assist devices.Business Wire BlogCorWave Achieves Major Regulatory Milestone with ISO 13485 Certification Across its Entire OperationsCorWave, a French cardiac assist device company, announced ISO 13485 certification for its entire operations, covering design, manufacturing, distribution, and servicing of its LVADs. The certification, awarded after an independent audit, marks a regulatory milestone toward commercialization. CEO Louis de Lillers said it enables confidence in the company's pivotal trial.openPR.comIn-depth Examination of Segments, Industry Trends, and Key Competitors in the Left Ventricular Assist Devices MarketThe global left ventricular assist devices market is projected to reach $2.78 billion by 2030, growing at a compound annual growth rate of 10%, driven by an aging population, technological advancements, and expanding reimbursement coverage. In March 2025, Abbott Laboratories partnered with Cadrenal Therapeutics to support a clinical trial of tecarfarin for HeartMate 3 LVAD patients, aiming to advance anticoagulant therapies for cardiovascular device patients. CorWave SA successfully implanted its Left Ventricular Assisting System in a patient at St Vincent's Hospital in Sydney in September 2025, meeting primary safety and efficacy endpoints without device-related adverse events at 30 days.MorningstarCorWave Strengthens Its Leadership Team with Two Key AppointmentsCorWave, a French medical device company developing innovative cardiac assist devices, announced the appointments of Andreas Fleischli as Chief Technology Officer and Daniel Lexcen as Vice President Clinical & Scientific Affairs to strengthen its leadership as it scales its clinical program and industrial setup. Andreas Fleischli brings approximately 30 years of LVAD development expertise, having previously worked at Thoratec, while Daniel Lexcen joins from Medtronic where he led global clinical research for cardiac rhythm. The hires complete CorWave's leadership team as the company progresses toward a pivotal clinical trial and CE marking for its undulating membrane heart pump, which completed its first clinical implants in May 2025.FinSMEsCorWave Raises €26M in Second Closing of Series C FundingCorWave, a French cardiac assist device developer, raised €26M in a second Series C round led by Bpifrance, bringing total funding to €61M. The company will use the funds to finance next development stages. Founded in 2021, it uses wave membrane technology to mimic healthy heart function.Business Wire BlogCorWave Announces Second Closing of Its Series C Funding at €61M to Finance Its First Industrial DeploymentCorWave raised €61 million in a second Series C round to fund its first industrial deployment and clinical trials. The SPI fund, managed by Bpifrance, invested €15 million, with European investors contributing €11 million. The company will soon inaugurate its manufacturing facility in Clichy.MaddynessCette startup lève 61 millions d’euros et industrialise sa lutte contre l’insuffisance cardiaqueFrench medtech CorWave has secured a 61 million euro Series C funding round led by SPI and international family groups to industrialize its innovative wave-like cardiac assist pump technology. This investment follows previous backing from entities like the EIC Fund and aims to scale manufacturing for a market valued at over $700 million annually, challenging incumbent Abbott. The funds will support the acquisition of precision machinery and the qualification of pre-series devices for clinical use.Les EchosCorWave rallonge sa série C de 26 M€CorWave has closed its Series C funding round with an additional 26 million euros, bringing the total raised since 2021 to 61 million euros. The medtech company secured investments from Bpifrance (15 million), SPI fund, Exor Ventures, and Vlerick Group.BioSpaceCorWave Announces Second Closing of Its Series C Funding at €61M to Finance Its First Industrial DeploymentCorWave raised 61 million euros to fund its first industrial deployment and entry into clinical trials, with major contributions from the SPI fund managed by Bpifrance and other European investors. This capital increase includes a €15 million investment from the SPI fund and marks a proactive step towards CorWave's goal of becoming a leading medtech company with its innovative wave membrane heart pump technology. The funding will support CorWave's ongoing development and manufacturing capabilities in France.trib.alEU Deploys Region’s Largest VC Fund to Create Local UnicornsThe European Innovation Council launched a 3-billion-euro venture capital fund to support health and deep-tech startups. It invested 15 million euros of its 35 million raised in January into CorWave, a French implantable heart pump startup.